The impact of albumin conjugation on the cytotoxic properties of cisplatin, oxaliplatin and auranofin in cancer cells

Abstract

The role of human serum albumin (HSA) in the delivery of anticancer metallodrugs remains unclear and requires further investigation. To this end, bioconjugates of HSA with the metallodrugs cisplatin (CIS), oxaliplatin (OXA) and auranofin (AF) were prepared, characterised by ESI-MS and ICP, and tested for their cytotoxic properties in A2780 and HCT116 cancer cells. Significant differences in the biological activity of the two Pt bioconjugates compared to the Au bioconjugate emerged, which are interpreted and discussed in the context of the available literature.